chemieunternehmen.com

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec’s assay development and screening capabilities to support the Jain Foundation’s goals of understanding and curing dysferlinopathy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-announce-extension-of-research-collaboration-in-skeletal-muscular-dystrophy-diseases-5153

Evotec AG today reported financial results and corporate updates for the first half of 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-h1-2013-results-5151

Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-dow-agrosciences-announce-collaboration-on-cellular-target-profiling-5147

Evotec AG today announced that it will close its Chemistry Operations in Thane, India. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-realign-discovery-chemistry-operations-5145

Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-development-of-new-class-of-antibacterials-5137

Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012- Q1 2013 revenues amounted to EUR 17.1 m (2012: EUR 20.1 m); up 5% compared to Q1 2012 revenues of EUR 16.2 m on a … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-q1-2013-driving-innovation-efficiency-5135

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/dana-farbers-belfer-institute-for-applied-cancer-science-and-evotec-establish-collaboration-in-oncology-5131

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-compound-management-capability-to-east-coast-of-the-united-states-5129

Evotec AG today announced an auspicious step in research from Harvard University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-hormone-to-treat-diabetes-published-in-cell-5127